Contact us to place a job advertisement on this page
Lecturer/Associate Professor in Stem Cell Biology and Regenerative Medicine
MRC Doctoral Training Programme Studentship, University of Glasgow, Glasgow, Scotland
Director, Translational Medicine & Clinical
To undertake research within the areas of Stem Cell Biology and Regenerative Medicine and to carry out associated teaching and administrative duties within the Reading School of Pharmacy.
Main duties and responsibilities
The University of Reading is building on its highly successful research in cell-based therapy through the appointment of a new post at Lecturer or Associate Professor level in Stem Cell Biology and Regenerative Medicine. In particular, we welcome applicants whose research complements our current research related to Cellular and Molecular Neuroscience or Cardiovascular Biology. Scientists working on cell-based therapy or in related fields such as fundamental stem cell biology with implications for neural/cardiac regeneration and clinical translation are particularly welcome. Applicants should demonstrate internationally competitive research expertise (with an acknowledged international reputation for an Associate Professor appointment), and an appropriate track record of innovation in the field of stem cell biology and regenerative medicine. The post holder will be based in the School of Pharmacy.
You will have:
In your application, please indicate whether you are applying at Lecturer or Associate Professor level.
Closing date is 8 August 2014.
To formally apply please visit www.reading.ac.uk/jobs or contact Human Resources, University of Reading, Whiteknights, PO Box 217, Reading RG6 6AH. Telephone +44(0)118 378 6771 (voicemail). Please quote the relevant reference number SA03314.
Project title: Suppression of IL-6 signalling by BMP4: a "missing link" in the development of pulmonary arterial hypertension?
Supervisors: Dr Tim Palmer and Professor Mandy MacLean
Project Summary: Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vasculature. Heritable PAH is associated with haploinsuffiency of the bone morphogenetic protein receptor II (BMPRII) leading to pulmonary vascular remodelling. Current therapeutic options simply relieve symptoms such as breathlessness, and so there is an urgent need to identify processes that could be targeted pharmacologically to arrest and/or reverse disease progression. Our original hypothesis is that one important consequence of defective BMP4/BMPR-II signalling is a reduced ability to inhibit IL-6-mediated trans-signalling in the pulmonary vasculature via induction of "suppressor of cytokine signaling 3" (SOCS3), and that this contributes to the chronic pulmonary inflammation observed in PAH. To test this hypothesis, the student will pursue an integrated programme of work that brings together the complimentary expertise of the two supervisors. This will involve A) Identifying the signalling pathways and transcription factors responsible for BMP4-mediated induction of SOCS3, B) Assessing IL-6 responses in pulmonary vascular cells from control and PAH patients, and C) Examining the translational potential of these findings using established in vivo models of PAH in mice in which IL-6 signalling complexes have been rendered resistant to inhibition by SOCS3.
Training: The project will provide opportunities for inter-disciplinary training in molecular cell biology and cutting edge technologies to examine cell signalling networks, as well providing training in cardiovascular physiology and in vivo whole animal research techniques. This will be supported by an extensive generic and transferable skills training programme provided by the College of Medical, Veterinary and Life Sciences Graduate School.
The studentship will be carried out within the Institute of Cardiovascular and Medical Sciences, which was recently designated as a BHF Centre of Excellence due to the outstanding training environment and opportunities for collaborative translational research.
Details: This is a fully funded 3.5-year PhD studentship commencing in October 2014. Applicants will normally be expected to reside (or have residency) within the UK. EU nationals will have to demonstrate that they have spent the three years prior to application resident in the UK (this can include residence whilst undertaking undergraduate study). Applicants should have obtained, or expect to obtain a 2:1 or 1st class Honours degree in Biochemistry, Pharmacology or a related subject. The financial package will include a 3.5 year stipend (currently £13,726 per annum), approved University fees, Research Training Support Grant and a conference allowance.
Interested students should contact Dr. Tim Palmer (Tim.Palmer@glasgow.ac.uk) for more information in the first instance.
Jim Gleeson at CK Clinical is recruiting for a Director, Translational Medicine & Clinical Pharmacology for a permanent position with a successful and dynamic international pharmaceutical company. The position will be based at their offices in the Home Counties.
Responsibilities: As the Director, Translational Medicine & Clinical Pharmacology your role will be to lead the early clinical development project team and to represent that team both internally and externally.
Specific duties will include:
Qualifications: As the Director, Translational Medicine & Clinical Pharmacology, you will require the following:
For more information or to apply for this Director, Translational Medicine & Clinical Pharmacology position please contact Jim Gleeson or call +44 (0)1438 842973. Alternatively please apply online now. CK Clinical is an Equal Opportunities employer and welcomes applications from all who meet our selection criteria. If you do not hear back from us within five working days of your application for this role, it means that on this occasion you have not been shortlisted for the next stage of the recruitment campaign.
Entitlement to work in the EEA is essential. Please quote reference CL28364 in all correspondence.